Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GTCR completes sale of Ovation to Lundbeck
Ovation has received $600 million of cash consideration at closing and will receive up to an additional $300 million based on certain regulatory milestones for Sabril (vigabatrin), a
Ovation has received $600 million of cash consideration at closing and will receive up to an additional $300 million based on certain regulatory milestones for Sabril (vigabatrin), a
Engle’s background also includes senior executive positions with Merck Generics Group, a division of Merck KGaA, and Allergan, Inc. “I’m very pleased that Mel has agreed to join
Canada-based ConjuChem Biotechnologies, which is engaged in the discovery of therapeutics with an initial focus on diabetes, has reported a net loss of $5.83m, or $0.02 per share,
Intravascular ultrasound technology enables physicians to see detailed images inside the heart and coronary arteries. The company said the iCross catheter would be available immediately in the US.
The lawsuits are based on abbreviated new drug applications (ANDA) filed by Teva and Mylan seeking permission to manufacture and market a generic version of Tarceva before the
Biolase Technology, a dental laser company, has reported a net loss of $5.29m, or $0.22 per share, for the fourth quarter of 2008, compared to a net loss
Prior to joining Alvine Pharmaceuticals, Dr Adelman was senior vice president of development and chief medical officer at Sunesis Pharmaceuticals. Prior to that, Dr Adelman served in various
Impax Pharmaceuticals will utilize its 66 neurology-focused sales force to promote Pristiq (desvenlafaxine), a serotonin-norepinephrine reuptake inhibitor as a treatment for adult patients with major depressive disorder. As
The cooperative R&D agreement with Maxim Biotech will initially focus on the development of a family of life science research reagent tool kits which can be used to
The company has also announced that William Rueckert has resigned from its board, and has accepted a position on the board of the company’s 72% shareholder, Novogen. Ms